Pharmaceutical

Request for TOC Request for Sample
BUY NOW

U.S. Psychedelic Drugs Market - Industry Trends and Forecast to 2029

Pharmaceutical | Upcoming Report | Apr 2022 | Country Level | 350 Pages | No of Tables: 220 | No of Figures: 60

Report Description

U.S. Psychedelic Drugs Market, By Source (Synthetic, Natural), Type (Empathogens, Dissociatives, Others), Drugs (Gamma-Hydroxybutyric Acid, Ketamine, Psilocybin, Others), Application (Narcolepsy, Treatment Resistant Depression, Major Depressive Disorder, Opiate Addiction, Post-Traumatic Stress Disorder, Others), Route of Administration (Oral, Inhalation, Injectable), End-User (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy) – Industry Trends and Forecast to 2029.

Market Analysis and Size

In recent years, the psychedelic drugs market is anticipated to grow rapidly during the forecast period. People are becoming more aware of mental health issues around the world. Mental health illnesses affect 13% of the world's population, according to a research published by the World Health Organization (WHO) in 2021. As per the report, one out of every five years is spent disabled due to mental health issues. People have sought treatment because of their severe conditions. Furthermore, some groups have initiated public awareness campaigns to promote the use of psychedelic medicines to treat mental illnesses.

Data Bridge Market Research analyses that the psychedelic drugs market was valued at USD 2834.72 million in 2021 and is expected to reach USD 9818.68 million by 2029, registering a CAGR of 16.8% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Psychedelic drugs are used to enhance or change sensory perceptions, cognitive processes, energy levels and spiritual experiences. The three forms of psychedelic drugs are empathogens, dissociative drugs, and serotonergic drugs. These drugs are used to treat major depressive disorder, treatment-resistant depression, panic disorder, post-traumatic stress disorder, and opiate addiction, among other conditions.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Source (Synthetic, Natural), Type (Empathogens, Dissociatives, Others), Drugs (Gamma-Hydroxybutyric Acid, Ketamine, Psilocybin, Others), Application (Narcolepsy, Treatment Resistant Depression, Major Depressive Disorder, Opiate Addiction, Post-Traumatic Stress Disorder, Others), Route of Administration (Oral, Inhalation, Injectable), End User (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy)

Market Players Covered

Avadel (Ireland), Celon Pharma S.A. (Poland), Johnson & Johnson Private Limited (US), Hikma Pharmaceuticals PLC (UK), Amneal Pharmaceuticals LLC. (US), NeuroRx, Inc. (US), Jazz Pharmaceuticals, Inc. (Ireland), COMPASS (UK), Develco Pharma Schweiz AG (Switzerland), Douglas Pharmaceuticals Limited (New Zealand)

Market Opportunities

  • Increase in the number of emerging markets
  • Increase in the number of research and development activities
  • Surge in drug approvals and new product launches
  • Rising investment for the development of advanced technologies

U.S. Psychedelic Drugs Market Dynamics

Drivers

  • Increasing prevalence of depression and mental disorders

Increased use of illicit substances has increased depression and mental problems. As a result of the rising prevalence of depression and mental diseases, demand for psychedelic substances is predicted to rise, propelling the industry forward.

  • Rising awareness towards mental health

Psychedelic substances have become more well-known due to advertisements, public awareness initiatives, and other means. People have been encouraged to choose the proper treatment for mental disorders processes and specialists due to the awareness campaigns, which have increased demand for psychedelic medications. As a result, increased mental health awareness is likely to be a key driver of market expansion.

  • Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of psychedelic drugs market is the rising healthcare expenditure which helps in improving its infrastructure.

Furthermore, the decentralization of pharmacies will expand the psychedelic drugs market. Additionally, high disposable income and increasing acceptance of psychedelic drugs for the treatment of depression will expand the psychedelic drugs market. Along with this, rising geriatric population and introduction of novel psychedelic drugs will enhance the growth rate of the market.

Opportunities

  • Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the psychedelic drugs market growth. Along with this, surge in drug approvals and new product launches will further propel the 'market's growth rate.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the psychedelic drugs market growth during the forecast period.

Restraints/Challenges

On the other hand, the delay in the drug approval process and poor order communication between physicians and pharmacists will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the psychedelic drugs market. Additionally, strict regulatory policies and surging side effects of psychedelic drugs will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This psychedelic drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the psychedelic drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Psychedelic drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on U.S. Psychedelic Drugs Market

Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country, prompting the World Health Organization (WHO) to declare it a public health emergency.

The market is growing due to increased demand for psychedelic drugs during the COVID-19 outbreak. COVID-19 infection rates were expanding over the world. People all throughout the world faced great trauma and stress as a result of the sudden imposition of the lockdown by governments across the globe.

Recent Development

  • In January 2020, Janssen Pharmaceuticals, Inc,. submitted a Type II Varian Application for SPRAVATO nasal spray to the European Medicines Agency. The proposal requests that nasal spray be used more widely as an acute, short-term therapy for depression symptoms. This would assist the business in generating revenue.

U.S. Psychedelic Drugs Market Scope

The psychedelic drugs market is segmented on the basis source, type, drugs, application, route of administration, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Source

  • Synthetic
  • Natural

Type

  • Empathogens
  • Dissociatives
  • Others

Drugs

  • Gamma-Hydroxybutyric Acid
  • Ketamine
  • Psilocybin
  • Others

Application

  • Narcolepsy
  • Treatment Resistant Depression
  • Major Depressive Disorder
  • Opiate Addiction
  • Post-Traumatic Stress Disorder
  • Others

Route of Administration

  • Oral
  • Inhalation
  • Injectable

End User

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Distribution Channel

  • Hospitals Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Competitive Landscape and U.S. Psychedelic Drugs Market Share Analysis

The psychedelic drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, North America presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to psychedelic drugs market.

Some of the major players operating in the U.S. psychedelic drugs market are:

  • Avadel (Ireland)
  • Celon Pharma S.A. (Poland)
  • Johnson & Johnson Private Limited (US)
  • Hikma Pharmaceuticals PLC (UK)
  • Amneal Pharmaceuticals LLC. (US)
  • NeuroRx, Inc. (US)
  • Jazz Pharmaceuticals, Inc. (Ireland)
  • COMPASS (UK)
  • Develco Pharma Schweiz AG (Switzerland)
  • Douglas Pharmaceuticals Limited (New Zealand)   


SKU-

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF U.S. PSYCHEDELIC DRUGS MARKET

1.4 LIMITATION

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 GEOGRAPHICAL SCOPE

2.2 YEARS CONSIDERED FOR THE STUDY

2.3 CURRENCY AND PRICING

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 MULTIVARIATE MODELLING

2.6 PRODUCTS LIFELINE CURVE

2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.8 VENDOR SHARE ANALYSIS

2.9 SECONDARY SOURCES

2.1 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PRACTICING PSYCHIATRISTS

4.2 PIPELINE PRODUCTS

5 EPIDEMIOLOGY

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 GROWING ACCEPTANCE OF PSYCHEDELIC DRUGS FOR TREATING DEPRESSION

6.1.2 INCREASING PREVALENCE OF DEPRESSION AND MENTAL DISORDERS

6.1.3 RISING AWARENESS TOWARDS MENTAL HEALTH

6.2 RESTRAINTS

6.2.1 STRINGENT REGULATIONS FOR PSYCHEDELIC DRUGS

6.2.2 HIGH COST OF PSYCHEDELIC DRUG

6.3 OPPORTUNITIES

6.3.1 INCREASING R&D ACTIVITIES IN PSYCHEDELIC DRUGS

6.3.2 BREAKTHROUGH THERAPY DESIGNATION BY REGULATORY AUTHORITY

6.4 CHALLENGE

6.4.1 SIDE EFFECTS ASSOCIATED WITH PSYCHEDELIC DRUGS

7 U.S. PSYCHEDELIC DRUGS MARKET, BY SOURCE

7.1 OVERVIEW

7.2 SYNTHETIC

7.3 NATURAL

8 U.S. PSYCHEDELIC DRUGS MARKET, BY TYPE

8.1 OVERVIEW

8.2 DISSOCIATIVE

8.3 EMPATHOGENS

8.4 SEROTONERGIC (CLASSICAL PSYCHEDELIC DRUGS)

9 U.S. PSYCHEDELIC DRUGS MARKET, BY APPLICATION

9.1 OVERVIEW

9.2 NARCOLEPSY

9.3 TREATMENT- RESISTANT DEPRESSION (TRD)

9.4 POST-TRAUMATIC STRESS DISORDER (PTSD)

9.5 MAJOR DEPRESSIVE DISORDER

9.6 OTHERS

10 U.S. PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION

10.1 OVERVIEW

10.2 ORAL

10.3 INTRANASAL

10.4 PARENTERAL

10.5 OTHERS

11 U.S. PSYCHEDELIC DRUGS MARKET, BY DRUGS

11.1 OVERVIEW

11.2 GAMMA-HYDROXYBUTYRIC ACID (GHB)

11.3 KETAMINE

11.4 3,4-METHYLENEDIOXYMETHAMPHETAMINE (ECSTASY)

11.5 PSILOCYBIN

12 U.S. PSYCHEDELIC DRUGS MARKET, BY END USER

12.1 OVERVIEW

12.2 HOSPITAL

12.3 SPECIALTY CLINICS

12.4 RESEARCH ORGANISATION

12.5 OTHERS

13 U.S. PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL

13.1 OVERVIEW

13.2 HOSPITAL PHARMACY

13.3 COMPOUNDING PHARMACY

13.4 OTHERS

14 U.S. PSYCHEDELIC DRUGS MARKET, COMPANY LANDSCAPE

15 COMPANY PROFILE

15.1 JAZZ PHARMACEUTICALS, INC.

15.1.1 COMPANY SNAPSHOT

15.1.2 REVENUE ANALYSIS

15.1.3 PRODUCT PORTFOLIO

15.1.4 PIPELINE PORTFOLIO

15.1.5 RECENT DEVELOPMENTS

15.2 JOHNSON & JOHNSON SERVICES, INC.

15.2.1 COMPANY SNAPSHOT

15.2.2 REVENUE ANALYSIS

15.2.3 PRODUCT PORTFOLIO

15.2.4 RECENT DEVELOPMENTS

16 POTENTIAL PLAYERS PROFILE

16.1 AVADEL PHARMACEUTICALS, PLC.

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 PIPELINE PORTFOLIO

16.1.4 RECENT DEVELOPMENT

16.2 AMNEAL PHARMACEUTICALS LLC.

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUE ANALYSIS

16.2.3 PIPELINE PORTFOLIO

16.2.4 RECENT DEVELOPMENT

16.3 CELON PHARMA SA

16.3.1 COMPANY SNAPSHOT

16.3.2 PIPELINE PORTFOLIO

16.3.3 RECENT DEVELOPMENT

16.4 COMPASS

16.4.1 COMPANY SNAPSHOT

16.4.2 PIPELINE PORTFOLIO

16.4.3 RECENT DEVELOPMENTS

16.5 DEVELCO PHARMA SCHWEIZ AG

16.5.1 COMPANY SNAPSHOT

16.5.2 PIPELINE PORTFOLIO

16.5.3 RECENT DEVELOPMENT

16.6 DOUGHLAS PHARMACEUTICALS LIMITED

16.6.1 COMPANY SNAPSHOT

16.6.2 PRODUCT PORTFOLIO

16.6.3 RECENT DEVELOPMENT

16.7 HIKMA PHARMACEUTICALS PLC

16.7.1 COMPANY SNAPSHOT

16.7.2 REVENUE ANALYSIS

16.7.3 PRODUCT PORTFOLIO

16.7.4 RECENT DEVELOPMENTS

16.8 NEURORX, INC.

16.8.1 COMPANY SNAPSHOT

16.8.2 PRODUCT PORTFOLIO

16.8.3 RECENT DEVELOPMENTS

16.9 USONAINSTITUTE.ORG

16.9.1 INSTITUTE SNAPSHOT

16.9.2 PIPELINE PORTFOLIO

16.9.3 RECENT DEVELOPMENTS

17 QUESTIONNAIRE

18 RELATED REPORT

List of Table

TABLE 1 MENTAL ILLNESS IN U.S. ADULTS IN 2018

TABLE 2 MENTAL DISORDERS IN THE U.S. ADULTS IN 2018

TABLE 3 MENTAL DISORDERS CAUSED BY USAGE OF SUBSTANCE DISORDERS IN WORLD IN 2017

TABLE 4 DRUG DEVELOPMENT PATHWAY FOR FDA APPROVAL OF NEW MEDICATIONS

TABLE 5 COST OF PSYCHEDELIC DRUGS

TABLE 6 PSYCHEDELIC DRUGS R&D ACTIVITIES

TABLE 7 U.S. PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2018-2027 (USD MILLION)

TABLE 8 U.S. PSYCHEDELIC DRUGS MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 9 U.S. PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 10 U.S. PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 11 U.S. PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2018-2027 (USD MILLION)

TABLE 12 U.S. PSYCHEDELIC DRUGS MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 13 U.S. PSYCHEDELIC DRUGS MARKET, BY END USER, 2018-2027 (VOLUME IN 100ML)

TABLE 14 U.S. PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

List of Figure

FIGURE 1 U.S. PSYCHEDELIC DRUGS MARKET: SEGMENTATION

FIGURE 2 U.S. PSYCHEDELIC DRUGS MARKET: DATA TRIANGULATION

FIGURE 3 U.S. PSYCHEDELIC DRUGS MARKET: DROC ANALYSIS

FIGURE 4 U.S. PSYCHEDELIC DRUGS MARKET : COUNTRY VS REGIONAL MARKET ANALYSIS

FIGURE 5 U.S. PSYCHEDELIC DRUGS MARKET : COMPANY RESEARCH ANALYSIS

FIGURE 6 U.S. PSYCHEDELIC DRUGS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 U.S. PSYCHEDELIC DRUGS MARKET: VENDOR SHARE ANALYSIS

FIGURE 8 U.S. PSYCHEDELIC DRUGS MARKET: SEGMENTATION

FIGURE 9 GROWING ACCEPTANCE OF PSYCHEDELIC DRUGS FOR TREATING DEPRESSION AND INCREASING PREVALENCE OF DEPRESSION AND MENTAL DISORDERS ARE DRIVING THE U.S. PSYCHEDELIC DRUGS MARKET IN THE FORECAST PERIOD OF 2020 TO 2027

FIGURE 10 SYNTHETIC IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE U.S. PSYCHEDELIC DRUGS MARKET IN 2020 & 2027

FIGURE 11 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGE OF U.S. PSYCHEDELIC DRUGS MARKET

FIGURE 12 MENTAL ILLNESS AMONG THE U.S. ADULTS IN 2018, BY DEMOGRAPHIC GROUP

FIGURE 13 MENTAL ILLNESS TREATMENT RATES AMONG THE U.S. ADULTS IN 2018, BY DEMOGRAPHIC GROUP:

FIGURE 14 MENTAL ILLNESS TREATMENT RATES AMONG THE U.S. ADULTS IN 2018, BY GENDER :

FIGURE 15 PREVALENCE OF DEPRESSIVE DISORDERS IN 2017

FIGURE 16 PREVALENCE OF ANXIETY DISORDERS IN 2017

FIGURE 17 PREVALENCE OF BIPOLAR DISORDER IN 2017

FIGURE 18 THE RIPPLE EFFECT OF MENTAL ILLNESS

FIGURE 19 MENTAL AND SUBSTANCE USE DISORDERS GLOBALLY IN 2017

FIGURE 20 PREVALENCE OF MENTAL HEALTH DISORDERS BY DISORDER TYPE IN WORLD IN 2017

FIGURE 21 MAGIC MUSHROOMS PRICES FOR RESEARCHERS IN THE U.S.

FIGURE 22 U.S. PSYCHEDELIC DRUGS MARKET: BY SOURCE, 2019

FIGURE 23 U.S. PSYCHEDELIC DRUGS MARKET: BY SOURCE, 2019-2027 (USD MILLION)

FIGURE 24 U.S. PSYCHEDELIC DRUGS MARKET: BY SOURCE, CAGR (2020-2027)

FIGURE 25 U.S. PSYCHEDELIC DRUGS MARKET: BY SOURCE, LIFELINE CURVE

FIGURE 26 U.S. PSYCHEDELIC DRUGS MARKET: BY TYPE, 2019

FIGURE 27 U.S. PSYCHEDELIC DRUGS MARKET: BY TYPE, 2019-2027 (USD MILLION)

FIGURE 28 U.S. PSYCHEDELIC DRUGS MARKET: BY TYPE, CAGR (2020-2027)

FIGURE 29 U.S. PSYCHEDELIC DRUGS MARKET: BY TYPE, LIFELINE CURVE

FIGURE 30 U.S. PSYCHEDELIC DRUGS MARKET: BY APPLICATION, 2019

FIGURE 31 U.S. PSYCHEDELIC DRUGS MARKET: BY APPLICATION, 2019-2027 (USD MILLION)

FIGURE 32 U.S. PSYCHEDELIC DRUGS MARKET: BY APPLICATION, CAGR (2020-2027)

FIGURE 33 U.S. PSYCHEDELIC DRUGS MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 34 U.S. PSYCHEDELIC DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2019

FIGURE 35 U.S. PSYCHEDELIC DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)

FIGURE 36 U.S. PSYCHEDELIC DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2027)

FIGURE 37 U.S. PSYCHEDELIC DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 38 U.S. PSYCHEDELIC DRUGS MARKET: BY DRUGS, 2019

FIGURE 39 U.S. PSYCHEDELIC DRUGS MARKET : BY DRUGS, 2019-2027 (USD MILLION)

FIGURE 40 U.S. PSYCHEDELIC DRUGS MARKET: BY DRUGS, CAGR (2020-2027)

FIGURE 41 U.S. PSYCHEDELIC DRUGS MARKET: BY DRUGS, LIFELINE CURVE

FIGURE 42 U.S. PSYCHEDELIC DRUGS MARKET: BY END USER, 2019

FIGURE 43 U.S. PSYCHEDELIC DRUGS MARKET, BY END USER, 2019-2027 (USD MILLION)

FIGURE 44 U.S. PSYCHEDELIC DRUGS MARKET: BY END USER, CAGR (2020-2027)

FIGURE 45 U.S. PSYCHEDELIC DRUGS MARKET: BY END USER, LIFELINE CURVE

FIGURE 46 U.S. PSYCHEDELIC DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2019

FIGURE 47 U.S. PSYCHEDELIC DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)

FIGURE 48 U.S. PSYCHEDELIC DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027)

FIGURE 49 U.S. PSYCHEDELIC DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 50 U.S. PSYCHEDELIC DRUGS MARKET: COMPANY SHARE 2019 (%)

View Infographics

FIGURE 1 U.S. PSYCHEDELIC DRUGS MARKET: SEGMENTATION

FIGURE 2 U.S. PSYCHEDELIC DRUGS MARKET: DATA TRIANGULATION

FIGURE 3 U.S. PSYCHEDELIC DRUGS MARKET: DROC ANALYSIS

FIGURE 4 U.S. PSYCHEDELIC DRUGS MARKET : COUNTRY VS REGIONAL MARKET ANALYSIS

FIGURE 5 U.S. PSYCHEDELIC DRUGS MARKET : COMPANY RESEARCH ANALYSIS

FIGURE 6 U.S. PSYCHEDELIC DRUGS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 U.S. PSYCHEDELIC DRUGS MARKET: VENDOR SHARE ANALYSIS

FIGURE 8 U.S. PSYCHEDELIC DRUGS MARKET: SEGMENTATION

FIGURE 9 GROWING ACCEPTANCE OF PSYCHEDELIC DRUGS FOR TREATING DEPRESSION AND INCREASING PREVALENCE OF DEPRESSION AND MENTAL DISORDERS ARE DRIVING THE U.S. PSYCHEDELIC DRUGS MARKET IN THE FORECAST PERIOD OF 2020 TO 2027

FIGURE 10 SYNTHETIC IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE U.S. PSYCHEDELIC DRUGS MARKET IN 2020 & 2027

FIGURE 11 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGE OF U.S. PSYCHEDELIC DRUGS MARKET

FIGURE 12 MENTAL ILLNESS AMONG THE U.S. ADULTS IN 2018, BY DEMOGRAPHIC GROUP

FIGURE 13 MENTAL ILLNESS TREATMENT RATES AMONG THE U.S. ADULTS IN 2018, BY DEMOGRAPHIC GROUP:

FIGURE 14 MENTAL ILLNESS TREATMENT RATES AMONG THE U.S. ADULTS IN 2018, BY GENDER :

FIGURE 15 PREVALENCE OF DEPRESSIVE DISORDERS IN 2017

FIGURE 16 PREVALENCE OF ANXIETY DISORDERS IN 2017

FIGURE 17 PREVALENCE OF BIPOLAR DISORDER IN 2017

FIGURE 18 THE RIPPLE EFFECT OF MENTAL ILLNESS

FIGURE 19 MENTAL AND SUBSTANCE USE DISORDERS GLOBALLY IN 2017

FIGURE 20 PREVALENCE OF MENTAL HEALTH DISORDERS BY DISORDER TYPE IN WORLD IN 2017

FIGURE 21 MAGIC MUSHROOMS PRICES FOR RESEARCHERS IN THE U.S.

FIGURE 22 U.S. PSYCHEDELIC DRUGS MARKET: BY SOURCE, 2019

FIGURE 23 U.S. PSYCHEDELIC DRUGS MARKET: BY SOURCE, 2019-2027 (USD MILLION)

FIGURE 24 U.S. PSYCHEDELIC DRUGS MARKET: BY SOURCE, CAGR (2020-2027)

FIGURE 25 U.S. PSYCHEDELIC DRUGS MARKET: BY SOURCE, LIFELINE CURVE

FIGURE 26 U.S. PSYCHEDELIC DRUGS MARKET: BY TYPE, 2019

FIGURE 27 U.S. PSYCHEDELIC DRUGS MARKET: BY TYPE, 2019-2027 (USD MILLION)

FIGURE 28 U.S. PSYCHEDELIC DRUGS MARKET: BY TYPE, CAGR (2020-2027)

FIGURE 29 U.S. PSYCHEDELIC DRUGS MARKET: BY TYPE, LIFELINE CURVE

FIGURE 30 U.S. PSYCHEDELIC DRUGS MARKET: BY APPLICATION, 2019

FIGURE 31 U.S. PSYCHEDELIC DRUGS MARKET: BY APPLICATION, 2019-2027 (USD MILLION)

FIGURE 32 U.S. PSYCHEDELIC DRUGS MARKET: BY APPLICATION, CAGR (2020-2027)

FIGURE 33 U.S. PSYCHEDELIC DRUGS MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 34 U.S. PSYCHEDELIC DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2019

FIGURE 35 U.S. PSYCHEDELIC DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)

FIGURE 36 U.S. PSYCHEDELIC DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2027)

FIGURE 37 U.S. PSYCHEDELIC DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 38 U.S. PSYCHEDELIC DRUGS MARKET: BY DRUGS, 2019

FIGURE 39 U.S. PSYCHEDELIC DRUGS MARKET : BY DRUGS, 2019-2027 (USD MILLION)

FIGURE 40 U.S. PSYCHEDELIC DRUGS MARKET: BY DRUGS, CAGR (2020-2027)

FIGURE 41 U.S. PSYCHEDELIC DRUGS MARKET: BY DRUGS, LIFELINE CURVE

FIGURE 42 U.S. PSYCHEDELIC DRUGS MARKET: BY END USER, 2019

FIGURE 43 U.S. PSYCHEDELIC DRUGS MARKET, BY END USER, 2019-2027 (USD MILLION)

FIGURE 44 U.S. PSYCHEDELIC DRUGS MARKET: BY END USER, CAGR (2020-2027)

FIGURE 45 U.S. PSYCHEDELIC DRUGS MARKET: BY END USER, LIFELINE CURVE

FIGURE 46 U.S. PSYCHEDELIC DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2019

FIGURE 47 U.S. PSYCHEDELIC DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)

FIGURE 48 U.S. PSYCHEDELIC DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027)

FIGURE 49 U.S. PSYCHEDELIC DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 50 U.S. PSYCHEDELIC DRUGS MARKET: COMPANY SHARE 2019 (%)

CHOOSE LICENCE TYPE
  • 2500.00
  • 2000.00
  • 1500.00
  • 3200.00
  • 5000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19